Serine-arginine protein kinases (SPRKs) constitute a relatively novel subfamily of serine-threonine kinases that specifically phosphorylate serine residues residing in serine-arginine/arginine-serine dipeptide motifs.
An overview of SRPK
Serine-arginine protein kinase (SRPK) is an important component of the serine-threonine protein kinase family found in recent years and plays an important role in the process of serine-specific phosphorylation. The SRPK family has the function of phosphorylating RNA splicing that contains RS-structured domains. Also， SRPKs play an important role in the selective splicing of Messenger RNA (mRNA), chromatin redistribution of somatic cells and sperm, cell cycle and p53 regulation, and cell metabolic signaling.
Major types of SRPK
There are many SRPKs have been found, such as SRPK1. SRPK1 is an RNA splicing kinase with high specificity for serine/arginine rich domain (RS domain). And SRPK1 can identify arginine and phosphorylate the serine in the development of tumors, leading to the progression of tumors.
Inhibition of SRPK
SRPIN340 is a specific inhibitor of SRPK, the IC 50 of which is 0.89 μM, and there is no significant inhibition of the other 140 kinds of kinases.
SRPK and diseases
Leukemia accounts for about one-third of the children's malignant tumors and in the developed regions of the big cities, malignant tumors are the leading cause of death in children, especially leukemia, thus, in-depth study of childhood leukemia prevention and treatment has important scientific significance and social significance. The treatment of leukemia is mainly treated by chemical drugs (chemotherapy). At present, most of the chemotherapeutic drugs used in clinic have low selectivity to tumor cells and normal cells, which can cause serious adverse reactions, such as bone marrow inhibition and severe infection, while killing tumor cells. Therefore, the targeted treatment of tumors has received increasing attention. Many studies have reported that SRPK1 plays an important role in the occurrence of multiple tumors. After interference with SRPK1 gene in tumor cells, it was found that the proliferation rate of tumor cells decreased, the apoptosis potential increased, and the sensitivity to chemotherapy drugs increased. In addition, the overexpression of SRPK1 in non-small cell lung cancer can promote the proliferation, invasion, metastasis and tumor formation of lung cancer cells.